Clinical Trials · NCT05996848
A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 300
- Start date
- Aug 2023
- Locations
- 37 sites, China
- Primary endpoint
- CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in body weight